Goldman Sachs Group Inc vs Smith & Nephew plc — how do they compare? Goldman Sachs Group Inc trades at $887 (market cap $256.98B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Goldman Sachs Group Inc is far larger — about 23.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Smith & Nephew plc for 120 Days on average.
| GS | SNN | |
|---|---|---|
Market Cap | $256.98B | $11.10B |
Volume | 1,748,426 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $1.15K | $37.17 |
52-Week Low | $744.60 | $26.42 |
Typical Hold Time | 101 Days | 120 Days |
Enterprise Value | $814.98B | $14.13B |
Dividend Yield | 2.27% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $887.21, down 1.11% on the day, with a bearish technical signal despite strong fundamental performance. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $20.98 significantly exceeding expectations of $14.47. Revenue growth accelerated to $58.28 billion in 2025, while net income margin improved to 29.46%. Analyst consensus remains positive with a $1,130 price target, though technical indicators show selling pressure.
GS presents a compelling value opportunity with a P/E of 13.63 below industry averages, supported by robust earnings growth and a 31.68% net income margin. However, negative operating cash flow of -$45.15 billion in 2025 and bearish technical momentum create near-term headwinds. The stock's 18.33% ROE and dividend yield of approximately 0.56% provide shareholder returns, but investors should monitor cash flow trends and FICC business performance highlighted in recent management commentary.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →